176 related articles for article (PubMed ID: 35781057)
1. Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism.
Palese F; Pontis S; Realini N; Torrens A; Ahmed F; Assogna F; Pellicano C; Bossù P; Spalletta G; Green K; Piomelli D
Pharmacol Res; 2022 Aug; 182():106338. PubMed ID: 35781057
[TBL] [Abstract][Full Text] [Related]
2. 7,8-dihydroxyflavone protects 6-OHDA and MPTP induced dopaminergic neurons degeneration through activation of TrkB in rodents.
Luo D; Shi Y; Wang J; Lin Q; Sun Y; Ye K; Yan Q; Zhang H
Neurosci Lett; 2016 May; 620():43-9. PubMed ID: 27019033
[TBL] [Abstract][Full Text] [Related]
3. Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence.
Avagliano C; Russo R; De Caro C; Cristiano C; La Rana G; Piegari G; Paciello O; Citraro R; Russo E; De Sarro G; Meli R; Mattace Raso G; Calignano A
Pharmacol Res; 2016 Nov; 113(Pt A):276-289. PubMed ID: 27616549
[TBL] [Abstract][Full Text] [Related]
4. Advances in the discovery of N-acylethanolamine acid amidase inhibitors.
Bandiera T; Ponzano S; Piomelli D
Pharmacol Res; 2014 Aug; 86():11-7. PubMed ID: 24798679
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors.
Malamas MS; Farah SI; Lamani M; Pelekoudas DN; Perry NT; Rajarshi G; Miyabe CY; Chandrashekhar H; West J; Pavlopoulos S; Makriyannis A
Bioorg Med Chem; 2020 Jan; 28(1):115195. PubMed ID: 31761726
[TBL] [Abstract][Full Text] [Related]
6. N-Acylethanolamine Acid Amidase contributes to disease progression in a mouse model of multiple sclerosis.
Pontis S; Palese F; Summa M; Realini N; Lanfranco M; De Mei C; Piomelli D
Pharmacol Res; 2020 Oct; 160():105064. PubMed ID: 32634582
[TBL] [Abstract][Full Text] [Related]
7.
Piomelli D; Scalvini L; Fotio Y; Lodola A; Spadoni G; Tarzia G; Mor M
J Med Chem; 2020 Jul; 63(14):7475-7490. PubMed ID: 32191459
[No Abstract] [Full Text] [Related]
8. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
9. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
10. Progress in the development of β-lactams as N-Acylethanolamine Acid Amidase (NAAA) inhibitors: Synthesis and SAR study of new, potent N-O-substituted derivatives.
Petracca R; Ponzano S; Bertozzi SM; Sasso O; Piomelli D; Bandiera T; Bertozzi F
Eur J Med Chem; 2017 Jan; 126():561-575. PubMed ID: 27915171
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
12. Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Borah A; Mohanakumar KP
Brain Res; 2010 Jul; 1344():192-9. PubMed ID: 20470760
[TBL] [Abstract][Full Text] [Related]
13. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
[TBL] [Abstract][Full Text] [Related]
14. NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI).
Li Y; Zhou P; Hu T; Ren J; Xu Y; Qiu Y; Lu C; Li Y
Eur J Pharmacol; 2021 Dec; 912():174561. PubMed ID: 34655598
[TBL] [Abstract][Full Text] [Related]
15. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
Sasso O; Moreno-Sanz G; Martucci C; Realini N; Dionisi M; Mengatto L; Duranti A; Tarozzo G; Tarzia G; Mor M; Bertorelli R; Reggiani A; Piomelli D
Pain; 2013 Mar; 154(3):350-360. PubMed ID: 23218523
[TBL] [Abstract][Full Text] [Related]
16. Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.
Jin W; Yang L; Yi Z; Fang H; Chen W; Hong Z; Zhang Y; Zhang G; Li L
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32326173
[TBL] [Abstract][Full Text] [Related]
17. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
[TBL] [Abstract][Full Text] [Related]
18. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
[TBL] [Abstract][Full Text] [Related]
20. N-acylethanolamine acid amidase (NAAA) inhibition decreases the motivation for alcohol in Marchigian Sardinian alcohol-preferring rats.
Fotio Y; Ciccocioppo R; Piomelli D
Psychopharmacology (Berl); 2021 Jan; 238(1):249-258. PubMed ID: 33037452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
